LIVIVO - Search results -

Search results

Result 1 - 10 of total 20

Search options

Article ; Online: Loss of Hematopoietic Cell-Derived Oncostatin M Worsens Diet-Induced Dysmetabolism in Mice.

Albiero, Mattia / Ciciliot, Stefano / Rodella, Anna / Migliozzi, Ludovica / Amendolagine, Francesco Ivan / Boscaro, Carlotta / Zuccolotto, Gaia / Rosato, Antonio / Fadini, Gian Paolo

Diabetes

2023 Volume 72, Issue 4, Page(s) 483–495

MeSH term(s)	Mice ; Animals ; Oncostatin M/genetics ; Oncostatin M/metabolism ; Glucose Intolerance/metabolism ; Adipose Tissue/metabolism ; Diet, High-Fat/adverse effects ; Hematopoietic Stem Cell Transplantation
Chemical Substances	Oncostatin M (106956-32-5)
Language	English
Publishing date	2023-01-19
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80085-5
ISSN	1939-327X ; 0012-1797
ISSN (online)	1939-327X
ISSN	0012-1797
DOI	10.2337/db22-0054
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.175: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Hematopoietic and Nonhematopoietic

Albiero, Mattia / D'Anna, Marianna / Bonora, Benedetta Maria / Zuccolotto, Gaia / Rosato, Antonio / Giorgio, Marco / Iori, Elisabetta / Avogaro, Angelo / Fadini, Gian Paolo

Antioxidants & redox signaling

2022 Volume 36, Issue 10-12, Page(s) 593–607

Abstract: Aims: ...

Abstract	Aims:
MeSH term(s)	Animals ; Diabetes Mellitus, Experimental/metabolism ; Hematopoietic Stem Cells/metabolism ; Humans ; Ischemia/metabolism ; Mice ; Mice, Inbred C57BL ; Src Homology 2 Domain-Containing, Transforming Protein 1/genetics ; Src Homology 2 Domain-Containing, Transforming Protein 1/metabolism ; Vascular Endothelial Growth Factor A/metabolism
Chemical Substances	SHC1 protein, human ; Src Homology 2 Domain-Containing, Transforming Protein 1 ; Vascular Endothelial Growth Factor A
Language	English
Publishing date	2022-01-04
Publishing country	United States
Document type	Clinical Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1483836-9
ISSN	1557-7716 ; 1523-0864
ISSN (online)	1557-7716
ISSN	1523-0864
DOI	10.1089/ars.2021.0097
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5488: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Biodistribution of Intratracheal, Intranasal, and Intravenous Injections of Human Mesenchymal Stromal Cell-Derived Extracellular Vesicles in a Mouse Model for Drug Delivery Studies.

Tolomeo, Anna Maria / Zuccolotto, Gaia / Malvicini, Ricardo / De Lazzari, Giada / Penna, Alessandro / Franco, Chiara / Caicci, Federico / Magarotto, Fabio / Quarta, Santina / Pozzobon, Michela / Rosato, Antonio / Muraca, Maurizio / Collino, Federica

Pharmaceutics

2023 Volume 15, Issue 2

Abstract: Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) are extensively studied as therapeutic tools. Evaluation of their biodistribution is fundamental to understanding MSC-EVs' impact on target organs. In our work, MSC-EVs were initially ... ...

Abstract	Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) are extensively studied as therapeutic tools. Evaluation of their biodistribution is fundamental to understanding MSC-EVs' impact on target organs. In our work, MSC-EVs were initially labeled with DiR, a fluorescent lipophilic dye, and administered to BALB/c mice (2.00 × 10
Language	English
Publishing date	2023-02-07
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527217-2
ISSN	1999-4923
ISSN	1999-4923
DOI	10.3390/pharmaceutics15020548
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Collagen VI promotes recovery from colitis by inducing lymphangiogenesis and drainage of inflammatory cells.

Molon, Sibilla / Brun, Paola / Scarpa, Melania / Bizzotto, Dario / Zuccolotto, Gaia / Scarpa, Marco / Fassan, Matteo / Angriman, Imerio / Rosato, Antonio / Braghetta, Paola / Castagliuolo, Ignazio / Bonaldo, Paolo

The Journal of pathology

2023 Volume 260, Issue 4, Page(s) 417–430

Abstract: Despite a number of studies providing evidence that the extracellular matrix (ECM) is an active player in the pathogenesis of intestinal inflammation, knowledge on the actual contribution of specific ECM molecules in the progression of inflammatory bowel ...

Abstract	Despite a number of studies providing evidence that the extracellular matrix (ECM) is an active player in the pathogenesis of intestinal inflammation, knowledge on the actual contribution of specific ECM molecules in the progression of inflammatory bowel disease (IBD) remains scant. Here, we investigated the role of a major ECM protein, collagen VI (ColVI), in gut homeostasis and elucidated the impact of its deregulation on the pathophysiology of IBD. To this end, we combined in vivo and ex vivo studies on wild type and ColVI-deficient (Col6a1
MeSH term(s)	Animals ; Mice ; Lymphangiogenesis ; Collagen Type VI/genetics ; Colitis/chemically induced ; Colitis/genetics ; Crohn Disease ; Inflammatory Bowel Diseases ; Mice, Knockout ; Inflammation ; Drainage
Chemical Substances	Collagen Type VI
Language	English
Publishing date	2023-06-05
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	3119-7
ISSN	1096-9896 ; 0022-3417
ISSN (online)	1096-9896
ISSN	0022-3417
DOI	10.1002/path.6092
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.12: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB "Super-Stimulation".

Zuccolotto, Gaia / Penna, Alessandro / Fracasso, Giulio / Carpanese, Debora / Montagner, Isabella Monia / Dalla Santa, Silvia / Rosato, Antonio

Frontiers in oncology

2021 Volume 11, Page(s) 708073

Abstract: Prostate cancer (PCa) is the second leading cause of malignancy-related mortality in males in the Western world. Although treatment like prostatectomy and radiotherapy for localized cancer have good results, similar positive outcomes are not achieved in ... ...

Abstract	Prostate cancer (PCa) is the second leading cause of malignancy-related mortality in males in the Western world. Although treatment like prostatectomy and radiotherapy for localized cancer have good results, similar positive outcomes are not achieved in metastatic PCa. Consequently, these aggressive and metastatic forms of PCa urgently need new methods of treatment. We already described an efficient and specific second-generation (2G) Chimeric Antigen Receptor (CAR) against Prostate Specific Membrane Antigen (PSMA), a glycoprotein overexpressed in prostate cancer and also present on neovasculature of several tumor entities. In an attempt to improve efficacy and
Language	English
Publishing date	2021-09-29
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2021.708073
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Prolonging the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®): An orthogonal assessment of physicochemical, biological and microbiological properties of original opened glass vials and diluted saline preparations.

Carpanese, Debora / Rossi, Valentina / Di Paolo, Veronica / Quintieri, Luigi / Penna, Alessandro / Zuccolotto, Gaia / Sebellin, Jessica / Saran, Camilla / Pipitone, Francesca / Miolo, Giorgia / De Diana, Elisabetta / Realdon, Nicola / Rigamonti, Nicoletta / Di Sarra, Francesca / Coppola, Marina / Rosato, Antonio

International journal of pharmaceutics

2023 Volume 649, Page(s) 123643

Abstract: The two anti-epidermal growth factor receptor monoclonal antibodies (mAbs) cetuximab and panitumumab are the pillars for the treatment of EGFR-positive, KRAS wild-type metastatic colorectal cancers. However, stability data of these mAbs are generally ... ...

Abstract	The two anti-epidermal growth factor receptor monoclonal antibodies (mAbs) cetuximab and panitumumab are the pillars for the treatment of EGFR-positive, KRAS wild-type metastatic colorectal cancers. However, stability data of these mAbs are generally missing or incomplete. Here, we report for the first time an orthogonal analysis of the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®), either undiluted vial leftovers or saline dilutions in polyolefin/polyamide infusion bags. All samples were stored at 2-8 °C protected from light, according to their summary of product characteristics (SmPCs). Alternatively, opened vials and preparations were maintained at 25 °C for 15 h, and then stored again at 2-8 °C protected from light to mimic a temporary interruption of the cold chain. Vial leftovers proved stable up to 180 days when stored according to their SmPCs, while compounded preparations in infusion bags maintained their physiochemical, biological and microbiological stability up to 30 days. Additionally, no changes were detected up to 30 days for the same samples undergoing a thermal excursion. Our results provide additional rationale to the SmPCs, crucial especially in the case of reassignment and pre-preparation of bags. This information will allow hospitals to achieve significant cost savings, and better organization of the entire therapeutic process.
MeSH term(s)	Humans ; Panitumumab/therapeutic use ; Cetuximab ; Colorectal Neoplasms/drug therapy ; Antibodies, Monoclonal ; Antineoplastic Agents ; Saline Solution
Chemical Substances	Panitumumab (6A901E312A) ; Cetuximab (PQX0D8J21J) ; Antibodies, Monoclonal ; Antineoplastic Agents ; Saline Solution
Language	English
Publishing date	2023-11-30
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	428962-6
ISSN	1873-3476 ; 0378-5173
ISSN (online)	1873-3476
ISSN	0378-5173
DOI	10.1016/j.ijpharm.2023.123643
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1409: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.

Montagner, Isabella Monia / Penna, Alessandro / Fracasso, Giulio / Carpanese, Debora / Dalla Pietà, Anna / Barbieri, Vito / Zuccolotto, Gaia / Rosato, Antonio

Cells

2020 Volume 9, Issue 6

Abstract: Prostate cancer (PCa) has become the most common cancer among males in Europe and the USA. Adoptive immunotherapy appears a promising strategy to control the advanced stages of the disease by specifically targeting the tumor, in particular through ... ...

Abstract	Prostate cancer (PCa) has become the most common cancer among males in Europe and the USA. Adoptive immunotherapy appears a promising strategy to control the advanced stages of the disease by specifically targeting the tumor, in particular through chimeric antigen receptor T (CAR-T) cell therapy. Despite the advancements of CAR-T technology in the treatment of hematological malignancies, solid tumors still represent a challenge. To overcome current limits, other cellular effectors than T lymphocytes are under study as possible candidates for CAR-engineered cancer immunotherapy. A novel approach involves the NK-92 cell line, which mediates strong cytotoxic responses against a variety of tumor cells but has no effect on non-malignant healthy counterparts. Here, we report a novel therapeutic approach against PCa based on engineering of NK-92 cells with a CAR recognizing the human prostate-specific membrane antigen (PSMA), which is overexpressed in prostatic neoplastic cells. More importantly, the potential utility of NK-92/CAR cells to treat PCa has not yet been explored. Upon CAR transduction, NK-92/CAR cells acquired high and specific lytic activity against PSMA-expressing prostate cancer cells in vitro, and also underwent degranulation and produced high levels of IFN-γ in response to antigen recognition. Lethal irradiation of the effectors, a safety measure requested for the clinical application of retargeted NK-92 cells, fully abrogated replication but did not impact on phenotype and short-term functionality. PSMA-specific recognition and antitumor activity were retained in vivo, as adoptive transfer of irradiated NK-92/CAR cells in prostate cancer-bearing mice restrained tumor growth and improved survival. Anti-PSMA CAR-modified NK-92 cells represent a universal, off-the-shelf, renewable, and cost-effective product endowed with relevant potentialities as a therapeutic approach for PCa immunotherapy.
MeSH term(s)	Adoptive Transfer ; Animals ; Cell Degranulation ; Cell Line, Tumor ; Cell Proliferation ; Cell- and Tissue-Based Therapy ; Cytotoxicity, Immunologic ; Disease Models, Animal ; Humans ; Interferon-gamma/metabolism ; Killer Cells, Natural/immunology ; Male ; Mice ; Mice, SCID ; NK Cell Lectin-Like Receptor Subfamily K/metabolism ; Neoplasm Metastasis ; Prostate-Specific Antigen/metabolism ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/pathology ; Receptors, Chimeric Antigen/metabolism ; Xenograft Model Antitumor Assays
Chemical Substances	NK Cell Lectin-Like Receptor Subfamily K ; Receptors, Chimeric Antigen ; Interferon-gamma (82115-62-6) ; Prostate-Specific Antigen (EC 3.4.21.77)
Language	English
Publishing date	2020-06-02
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2661518-6
ISSN	2073-4409 ; 2073-4409
ISSN (online)	2073-4409
ISSN	2073-4409
DOI	10.3390/cells9061382
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Inhibition of SGLT2 Rescues Bone Marrow Cell Traffic for Vascular Repair: Role of Glucose Control and Ketogenesis.

Albiero, Mattia / Tedesco, Serena / Amendolagine, Francesco Ivan / D'Anna, Marianna / Migliozzi, Ludovica / Zuccolotto, Gaia / Rosato, Antonio / Cappellari, Roberta / Avogaro, Angelo / Fadini, Gian Paolo

Diabetes

2021 Volume 70, Issue 8, Page(s) 1767–1779

Abstract: The mechanisms by which sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular outcomes in people with diabetes are incompletely understood. Recent studies show that SGLT2i may increase the levels of circulating cells with vascular ... ...

Abstract	The mechanisms by which sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular outcomes in people with diabetes are incompletely understood. Recent studies show that SGLT2i may increase the levels of circulating cells with vascular regenerative capacity, at least in part by lowering glycemia. In this study, we used mice with streptozotocin-induced diabetes treated with the SGLT2i dapagliflozin at a dose that reduced glucose levels by 20%. Dapagliflozin improved the diabetes-associated defect of hematopoietic stem cell mobilization after stimulation with granulocyte colony-stimulating factor. Dapagliflozin rescued the traffic of bone marrow (BM)-derived cells to injured carotid arteries and improved endothelial healing in diabetic mice. Defective homing of CD49d
Language	English
Publishing date	2021-04-26
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80085-5
ISSN	1939-327X ; 0012-1797
ISSN (online)	1939-327X
ISSN	0012-1797
DOI	10.2337/db20-1045
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.175: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy.

Bellone, Matteo / Bregni, Marco / Bronte, Vincenzo / Ugel, Stefano / Ferrucci, Pier Francesco / Di Nicola, Massimo / Nisticò, Paola / Zuccolotto, Gaia / Rosato, Antonio / Russo, Vincenzo / Sica, Antonio / Colombo, Mario P

Cancer immunology, immunotherapy : CII

2021 Volume 71, Issue 7, Page(s) 1777–1786

MeSH term(s)	Biological Therapy ; Cancer Vaccines ; Humans ; Immunotherapy ; Italy ; Neoplasms/therapy
Chemical Substances	Cancer Vaccines
Language	English
Publishing date	2021-11-09
Publishing country	Germany
Document type	Letter
ZDB-ID	195342-4
ISSN	1432-0851 ; 0340-7004
ISSN (online)	1432-0851
ISSN	0340-7004
DOI	10.1007/s00262-021-03104-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1237: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Diabetes-Associated Myelopoiesis Drives Stem Cell Mobilopathy Through an OSM-p66Shc Signaling Pathway.

Albiero, Mattia / Ciciliot, Stefano / Tedesco, Serena / Menegazzo, Lisa / D'Anna, Marianna / Scattolini, Valentina / Cappellari, Roberta / Zuccolotto, Gaia / Rosato, Antonio / Cignarella, Andrea / Giorgio, Marco / Avogaro, Angelo / Fadini, Gian Paolo

Diabetes

2019 Volume 68, Issue 6, Page(s) 1303–1314

Abstract: Diabetes impairs the mobilization of hematopoietic stem/progenitor cells (HSPCs) from the bone marrow (BM), which can worsen the outcomes of HSPC transplantation and of diabetic complications. In this study, we examined the oncostatin M (OSM)-p66Shc ... ...

Abstract	Diabetes impairs the mobilization of hematopoietic stem/progenitor cells (HSPCs) from the bone marrow (BM), which can worsen the outcomes of HSPC transplantation and of diabetic complications. In this study, we examined the oncostatin M (OSM)-p66Shc pathway as a mechanistic link between HSPC mobilopathy and excessive myelopoiesis. We found that streptozotocin-induced diabetes in mice skewed hematopoiesis toward the myeloid lineage via hematopoietic-intrinsic p66Shc. The overexpression of
MeSH term(s)	Adult ; Aged ; Animals ; Bone Marrow Transplantation ; Chemokine CXCL12/genetics ; Diabetes Mellitus/metabolism ; Diabetes Mellitus, Experimental/metabolism ; Female ; Granulocyte Colony-Stimulating Factor ; Hematopoietic Stem Cell Mobilization ; Hematopoietic Stem Cells/metabolism ; Humans ; Male ; Mesenchymal Stem Cells/metabolism ; Middle Aged ; Myelopoiesis/genetics ; Oncostatin M/genetics ; Oncostatin M/metabolism ; Signal Transduction ; Src Homology 2 Domain-Containing, Transforming Protein 1/genetics ; Src Homology 2 Domain-Containing, Transforming Protein 1/metabolism ; Stem Cells
Chemical Substances	Chemokine CXCL12 ; Cxcl12 protein, mouse ; Osm protein, mouse ; Shc1 protein, mouse ; Src Homology 2 Domain-Containing, Transforming Protein 1 ; Oncostatin M (106956-32-5) ; Granulocyte Colony-Stimulating Factor (143011-72-7)
Language	English
Publishing date	2019-04-01
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80085-5
ISSN	1939-327X ; 0012-1797
ISSN (online)	1939-327X
ISSN	0012-1797
DOI	10.2337/db19-0080
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.175: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito